Food proteins

Phase 1Small molecule

SStanford University

Food proteins is one of 11 small molecule programs targeting Food Allergy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Food AllergyActive, not recruiting

Food AllergyPhase 1

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Food Allergy

#DrugCompanyPhaseTrials

Calquence

Singulair

1 3

Xolair

Roche

Phase 3

5 4

Imbruvica

DUPIXENT

Ligelizumab

1 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

2 8

Cibinqo

Pfizer

Phase 1

1 9

Epiceram

SStanford University

Phase 3

1 10

Linvoseltamab

Regeneron

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Food Allergy1 trial

Single Center Food Allergy Oral Immunotherapy Study

Completed·SStanford University·Phase 1·NCT01490177·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Food proteins. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Food proteins compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Food proteins. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SStanford University

Food proteins

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Food Allergy1 trial

References

Drug Info

Quick Facts

Related News